Duration of adjuvant immune checkpoint inhibitors in hepatocellular carcinoma with high-risk recurrence factors: A prospective, multicentric cohort study

被引：0
|
作者：
Su, J-Y. [1 ]
Liu, S. [2 ]
Xu, X-L. [3 ]
Ou, J-J. [4 ]
Li, L. [1 ]
Ma, Y-L. [5 ]
Ma, L. [1 ]
Zhong, J-H. [1 ]
机构：
[1] Guangxi Med Univ, Canc Hosp, Hepatobiliary Surg, Nanning, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 8, Hepatobiliary Surg, Guigang, Peoples R China
[3] Peoples Hosp Wuzhou, Med Records & Stat Room, Wuzhou, Peoples R China
[4] Wuzhou Peoples Hosp, Hepatobiliary Surg, Wuzhou, Peoples R China
[5] Guangxi Med Univ, Canc Hosp, Pathol, Nanning, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.233
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
213P
引用
收藏
页码：S1485 / S1486
页数：2
相关论文
共 50 条
  • [41] Adjuvant transarterial chemoembolization after radical resection contributed to the outcomes of hepatocellular carcinoma patients with high-risk factors
    Gao, Zhendong
    Du, Gang
    Pang, Yuguang
    Fu, Zhihao
    Liu, Chongzhong
    Liu, Yi
    Zhou, Binghai
    Kong, Du
    Shi, Binyao
    Jiang, Zhengcheng
    Jin, Bin
    MEDICINE, 2017, 96 (33)
  • [42] Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?
    Jiang, Jingyu
    Huang, Haitao
    Chen, Ruihan
    Lin, Yimou
    Ling, Qi
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] IMMUNE CHECKPOINT SYSTEM FOR EARLY STAGE CERVICAL CANCER WITH HIGH-RISK FACTORS
    Takekuma, M.
    Takuma, O.
    Masato, A.
    Ayako, M.
    Emi, Y.
    Yuka, K.
    Nobuhiro, K.
    Nobutaka, T.
    Masakazu, A.
    Yasuyuki, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 895 - 895
  • [44] IMMUNE CHECKPOINT SYSTEM FOR EARLY STAGE CERVICAL CANCER WITH HIGH-RISK FACTORS
    Takekuma, M.
    Takuma, O.
    Masato, A.
    Ayako, M.
    Emi, Y.
    Yuka, K.
    Nobuhiro, K.
    Nobutaka, T.
    Masakazu, A.
    Yasuyuki, H.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 403 - 403
  • [45] The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
    Suksomboon, T.
    Sitthideatphaiboon, P.
    Phannajit, J.
    Katavetin, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1602 - S1602
  • [46] Overview of Immune Checkpoint Inhibitors Therapy for Hepatocellular Carcinoma, and The ITA.LI.CA Cohort Derived Estimate of Amenability Rate to Immune Checkpoint Inhibitors in Clinical Practice
    Giannini, Edoardo G.
    Aglitti, Andrea
    Borzio, Mauro
    Gambato, Martina
    Guarino, Maria
    Iavarone, Massimo
    Lai, Quirino
    Sandri, Giovanni Battista Levi
    Melandro, Fabio
    Morisco, Filomena
    Ponziani, Francesca Romana
    Rendina, Maria
    Russo, Francesco Paolo
    Sacco, Rodolfo
    Vigano, Mauro
    Vitale, Alessandro
    Trevisani, Franco
    Aliberti, C.
    Baccarani, U.
    Bhoori, S.
    Brancaccio, G.
    Burra, P.
    Cabibbo, G.
    Gardini, Casadei A.
    Carrai, P.
    Cillo, U.
    Conti, F.
    Cucchetti, A.
    D'Ambrosio, R.
    Dell'Unto, C.
    Dematthaeis, N.
    Di Costanzo, G. G.
    Di Sandro, S.
    Foschi, F. G.
    Fucilli, F.
    Galati, G.
    Gasbarrini, A.
    Giuliante, F.
    Ghinolfi, D.
    Grieco, A.
    Gruttaduria, S.
    Kostandini, A.
    Lenci, I
    Losito, F.
    Lupo, L. G.
    Manzia, T. M.
    Mazzocato, S.
    Mescoli, C.
    Miele, L.
    Muley, M.
    CANCERS, 2019, 11 (11)
  • [47] Transarterial chemoembolization combined with molecularly targeted agents plus immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a retrospective cohort study
    Jiang, Nan
    Zhong, Binyan
    Huang, Jintao
    Li, Wanci
    Zhang, Shuai
    Zhu, Xiaoli
    Ni, Caifang
    Shen, Jian
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [48] Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?
    Cai, Chao
    Zhang, Hui-Fang
    Yang, Nai-Bin
    Lu, Ming-Qin
    HEPATOLOGY INTERNATIONAL, 2022, 16 (02) : 480 - 481
  • [49] Immune checkpoint inhibitors in chronic hepatitis B: therapy or high-risk factor for reactivation?
    Chao Cai
    Hui-Fang Zhang
    Nai-Bin Yang
    Ming-Qin Lu
    Hepatology International, 2022, 16 : 480 - 481
  • [50] A RANDOMIZED PILOT PHASE II STUDY OF THALIDOMIDE AS ADJUVANT THERAPY IN PATIENT WITH HIGH RECURRENCE RISK HEPATOCELLULAR CARCINOMA
    Ho, M. -C.
    Hu, R. -H.
    Ho, C. -M.
    Chen, C. -N.
    Chang, K. -J.
    Lee, P. -H.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S35 - S35
12345